comscoreImmunotherapy to Treat Metastatic HER2-Positive Breast Cancer: ESMO 2019 Coverage

Immunotherapy to Treat Metastatic HER2-Positive Breast Cancer: ESMO 2019 Coverage

Dr. Leisha Emens discusses results from the KATE2 study.
Oct 14, 2019

At the European Society for Medical Oncology 2019 Congress, Dr. Emens presented overall survival results from the KATE2 study, which compared using the combination of Tecentriq, also called atezolizumab, and Kadcyla, also called T-DM1, to Kadcyla alone to treat HER2-positive metastatic breast cancer that had grown while being treated with Herceptin and chemotherapy.

Listen to the podcast to hear Dr. Emens discuss:

  • the design of the KATE2 study

  • why the study is encouraging, even though it didn't meet its primary endpoint

  • what the results mean for people diagnosed with HER2-positive metastatic breast cancer

  • her advice to people diagnosed with breast cancer who are interested in immunotherapy

About the guest
Leisha Emens headshot
Leisha Emens, MD, PhD

Dr. Leisha Emens is a professor of medicine in hematology/oncology at the University of Pittsburgh Medical Center Hillman Cancer Center. She is also co-leader of the Hillman Cancer Immunology and Immunotherapy Program, and director of translational immunotherapy for the Women's Cancer Research Center. Dr. Emens specializes in cancer immunotherapy, and her research focuses on the development and implementation of breast cancer immunotherapies (including vaccines and immune checkpoint inhibitors) in combination with traditional cancer treatments and other drugs that activate the immune system. Dr. Emens discloses that she has received research support from Merck, EMD-Serono, AstraZeneca, Genentech-Roche, Corvus, and Aduro. She has received honoraria from Vaccinex, Amgen, Syndax, Peregrine, Bayer, and Gritstone.

— Last updated on June 29, 2022, 2:47 PM

Lilly Oncology

This content made possible by Lilly Oncology.

Support to produce more content like this

Your donation goes directly to what you read, hear, and see on